Study #2017-0313
A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic Myelogenous Leukemia
Study Status
Open
Treatment Agent
Dexamethasone, Ponatinib, Venetoclax
Principal Investigator
Farhad Ravandi-Kashani
Description
There are 2 phases to this clinical research study: Phase 1 and Phase 2. The goal of Phase 1 is to find the highest tolerable dose of venetoclax that can be given in combination with ponatinib to patients with certain types of leukemia. The goal of Phase 2 is to learn if the highest tolerable dose combination found in Phase 1 can help to control Ph-positive ALL or CML. The safety of this drug combination will be studied in both phases.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Dexamethasone, Ponatinib, Venetoclax
Treatment Location: Only at MD Anderson
Sponsor: Abbvie
Study Status
IRB Review and Approval Date: 06/26/2018
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase I/Phase II
Physician name:
Farhad Ravandi-Kashani
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789